New drug combo targets tough cancers in early trial

NCT ID NCT06177171

Recruiting now Disease control Sponsor: Varun Monga, MBBS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a combination of two oral drugs, olaparib and ASTX727, in adults with advanced solid tumors that have mutations in genes like BRCA1, BRCA2, PALB2, ATM, or CHEK2. The main goals are to find the safest dose and to check for side effects. About 18 participants will take part, and the study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATM GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATM GENE MUTATION BRCA MUTATION BRCA1 MUTATION BRCA2 MUTATION CHECKPOINT KINASE 2 GENE MUTATION PALB2 GENE MUTATION

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.